Bluebird's US$2.8 million gene therapy becomes most expensive drug after US approval - CNA

The US Food and Drug Administration on Wednesday (Aug 17) approved bluebird bio's gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker priced it at a record US$2.8 million. The approval sent the company's shar…

The US Food and Drug Administration on Wednesday (Aug 17) approved bluebird bio's gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker priced it at a… [+1811 chars]

full article...